Drug
BI 764198
BI 764198: highest development phase Phase 3, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 764198 NCT07220083 | Phase 3 | Focal Segmental Glomerulosclerosis |
Latest
No recent events.
Follow BI 764198 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.